Published in J Thorac Cardiovasc Surg on September 01, 2010
Sp1 expression regulates lung tumor progression. Oncogene (2011) 1.20
The Mu opioid receptor promotes opioid and growth factor-induced proliferation, migration and Epithelial Mesenchymal Transition (EMT) in human lung cancer. PLoS One (2014) 0.95
Discovery of common SNPs in the miR-205/200 family-regulated epithelial to mesenchymal transition pathway and their association with risk for non-small cell lung cancer. Int J Mol Epidemiol Genet (2011) 0.87
The role of Axl in drug resistance and epithelial-to-mesenchymal transition of non-small cell lung carcinoma. Int J Clin Exp Pathol (2014) 0.87
Epithelial mesenchymal transition: a new insight into the detection of circulating tumor cells. ISRN Oncol (2012) 0.86
Silibinin synergizes with histone deacetylase and DNA methyltransferase inhibitors in upregulating E-cadherin expression together with inhibition of migration and invasion of human non-small cell lung cancer cells. J Pharmacol Exp Ther (2013) 0.85
Chemopreventive and anti-cancer efficacy of silibinin against growth and progression of lung cancer. Nutr Cancer (2013) 0.84
Independent of ErbB1 gene copy number, EGF stimulates migration but is not associated with cell proliferation in non-small cell lung cancer. Cancer Cell Int (2013) 0.82
miR-223/FBW7 axis regulates doxorubicin sensitivity through epithelial mesenchymal transition in non-small cell lung cancer. Am J Transl Res (2016) 0.76
Biomolecular and clinical practice in malignant pleural mesothelioma and lung cancer: what thoracic surgeons should know. Eur J Cardiothorac Surg (2014) 0.75
Gankyrin promotes epithelial-mesenchymal transition and metastasis in NSCLC through forming a closed circle with IL-6/ STAT3 and TGF-β/SMAD3 signaling pathway. Oncotarget (2016) 0.75
Cardamonin Suppresses TGF-β1-Induced Epithelial Mesenchymal Transition via Restoring Protein Phosphatase 2A Expression. Biomol Ther (Seoul) (2015) 0.75
The suppressive role of miR-542-5p in NSCLC: the evidence from clinical data and in vivo validation using a chick chorioallantoic membrane model. BMC Cancer (2017) 0.75
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol (2008) 7.01
Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail (2013) 4.98
Pulmonary complications after esophagectomy. Ann Thorac Surg (2002) 3.35
Prognostic factors for the survival of patients with esophageal carcinoma in the U.S.: the importance of tumor length and lymph node status. Cancer (2002) 2.82
What happens to patients undergoing lung cancer surgery? Outcomes and quality of life before and after surgery. Chest (2002) 2.79
Large animal models of heart failure: a critical link in the translation of basic science to clinical practice. Circ Heart Fail (2009) 2.72
Animal models of heart failure: a scientific statement from the American Heart Association. Circ Res (2012) 2.31
Matrix metalloproteinase-9 gene deletion facilitates angiogenesis after myocardial infarction. Am J Physiol Heart Circ Physiol (2005) 2.23
Cardiac support device modifies left ventricular geometry and myocardial structure after myocardial infarction. Circulation (2005) 2.14
Stereotactic body radiation therapy versus surgical resection for stage I non-small cell lung cancer. J Thorac Cardiovasc Surg (2010) 2.06
Optimum lymphadenectomy for esophageal cancer. Ann Surg (2010) 2.01
Region- and type-specific induction of matrix metalloproteinases in post-myocardial infarction remodeling. Circulation (2003) 1.95
Myocardial infarct expansion and matrix metalloproteinase inhibition. Circulation (2003) 1.91
Aortic dilatation with bicuspid aortic valves: cusp fusion correlates to matrix metalloproteinases and inhibitors. Ann Thorac Surg (2011) 1.88
Patient safety in the cardiac operating room: human factors and teamwork: a scientific statement from the American Heart Association. Circulation (2013) 1.86
Noninvasive targeted imaging of matrix metalloproteinase activation in a murine model of postinfarction remodeling. Circulation (2005) 1.82
Targeted myocardial microinjections of a biocomposite material reduces infarct expansion in pigs. Ann Thorac Surg (2008) 1.82
An analysis of multiple staging management strategies for carcinoma of the esophagus: computed tomography, endoscopic ultrasound, positron emission tomography, and thoracoscopy/laparoscopy. Ann Thorac Surg (2002) 1.80
Preoperative statin treatment is associated with reduced postoperative mortality and morbidity in patients undergoing cardiac surgery: an 8-year retrospective cohort study. J Thorac Cardiovasc Surg (2006) 1.78
Ineffectiveness of histone deacetylase inhibitors to induce apoptosis involves the transcriptional activation of NF-kappa B through the Akt pathway. J Biol Chem (2003) 1.73
Mitral regurgitation augments post-myocardial infarction remodeling failure of hypertrophic compensation. J Am Coll Cardiol (2008) 1.70
Management of acute esophageal necrosis syndrome. J Thorac Cardiovasc Surg (2011) 1.69
Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: relation to left ventricular remodeling. Circulation (2006) 1.69
Age-dependent changes in myocardial matrix metalloproteinase/tissue inhibitor of metalloproteinase profiles and fibroblast function. Cardiovasc Res (2004) 1.68
Angiotensin II receptor blockade does not improve left ventricular function and remodeling in subacute mitral regurgitation in the dog. J Am Coll Cardiol (2002) 1.65
Cardioprotective and antiapoptotic effects of heme oxygenase-1 in the failing heart. Circulation (2010) 1.64
Accurate molecular detection of non-small cell lung cancer metastases in mediastinal lymph nodes sampled by endoscopic ultrasound-guided needle aspiration. Chest (2005) 1.62
Accuracy of EUS in staging of T4 lung cancer. Gastrointest Endosc (2004) 1.60
Aprotinin in cardiac surgery: a review of conventional and novel mechanisms of action. Anesth Analg (2007) 1.57
Interrupted aortic arch in the adult. J Card Surg (2011) 1.56
Use of recombinant activated factor VII concentrate to control postoperative hemorrhage in complex cardiovascular surgery. Ann Thorac Surg (2008) 1.50
Administration of recombinant activated factor VII in the intensive care unit after complex cardiovascular surgery: clinical and economic outcomes. J Thorac Cardiovasc Surg (2011) 1.50
Standardized preoperative corticosteroid treatment in neonates undergoing cardiac surgery: results from a randomized trial. J Thorac Cardiovasc Surg (2011) 1.50
Surgical management of descending thoracic aortic disease: open and endovascular approaches: a scientific statement from the American Heart Association. Circulation (2010) 1.47
Accelerated LV remodeling after myocardial infarction in TIMP-1-deficient mice: effects of exogenous MMP inhibition. Am J Physiol Heart Circ Physiol (2005) 1.47
Matrix metalloproteinase-7 affects connexin-43 levels, electrical conduction, and survival after myocardial infarction. Circulation (2006) 1.46
A prospective, randomized study of endothelin and postoperative recovery in off-pump versus conventional coronary artery bypass surgery. J Cardiothorac Vasc Anesth (2004) 1.46
Deficiency of TIMP-1 exacerbates LV remodeling after myocardial infarction in mice. Am J Physiol Heart Circ Physiol (2002) 1.45
Selective spatiotemporal induction of matrix metalloproteinase-2 and matrix metalloproteinase-9 transcription after myocardial infarction. Am J Physiol Heart Circ Physiol (2006) 1.43
Expression of matrix metalloproteinases and endogenous inhibitors within ascending aortic aneurysms of patients with bicuspid or tricuspid aortic valves. J Thorac Cardiovasc Surg (2007) 1.42
Detection of telomerase expression in mediastinal lymph nodes of patients with lung cancer. Am J Respir Crit Care Med (2003) 1.42
Transforming growth factor-beta signaling in thoracic aortic aneurysm development: a paradox in pathogenesis. J Vasc Res (2008) 1.42
Matrix metalloproteinase abundance in human myocardial fibroblasts: effects of sustained pharmacologic matrix metalloproteinase inhibition. J Mol Cell Cardiol (2003) 1.42
Extracellular matrix remodeling following myocardial injury. Ann Med (2003) 1.41
Selective targeting and timing of matrix metalloproteinase inhibition in post-myocardial infarction remodeling. Circulation (2003) 1.40
Choosing wisely: cardiothoracic surgeons partnering with patients to make good health care decisions. Ann Thorac Surg (2013) 1.40
Sustained supervised practice on a coronary anastomosis simulator increases medical student interest in surgery, unsupervised practice does not. Ann Thorac Surg (2013) 1.39
Modulation of calcium transport improves myocardial contractility and enzyme profiles after prolonged ischemia-reperfusion. Ann Thorac Surg (2003) 1.39
Expression of matrix metalloproteinases and endogenous inhibitors within ascending aortic aneurysms of patients with Marfan syndrome. Circulation (2006) 1.32
Proteinase systems and thoracic aortic aneurysm progression. J Surg Res (2007) 1.32
Suberoylanilide hydroxamic acid induces Akt-mediated phosphorylation of p300, which promotes acetylation and transcriptional activation of RelA/p65. J Biol Chem (2006) 1.30
Pathways of matrix metalloproteinase induction in heart failure: bioactive molecules and transcriptional regulation. Cardiovasc Res (2006) 1.29
Epidemiology of esophageal cancer. Surg Clin North Am (2012) 1.29
Early postoperative outcomes and blood product utilization in adult cardiac surgery: the post-aprotinin era. Circulation (2011) 1.24
Mesenchymal cell transplantation and myocardial remodeling after myocardial infarction. Circulation (2009) 1.23
Regional heterogeneity within the aorta: relevance to aneurysm disease. J Thorac Cardiovasc Surg (2008) 1.23
Tumor necrosis factor-alpha and myocardial remodeling in progression of heart failure: a current perspective. Cardiovasc Res (2002) 1.21
Cellular mechanisms of tissue fibrosis. 2. Contributory pathways leading to myocardial fibrosis: moving beyond collagen expression. Am J Physiol Cell Physiol (2012) 1.21
Selective microRNA suppression in human thoracic aneurysms: relationship of miR-29a to aortic size and proteolytic induction. Circ Cardiovasc Genet (2011) 1.20
Early repair of moderate ischemic mitral regurgitation reverses left ventricular remodeling: a functional and molecular study. Circulation (2007) 1.20
Myosin light chain phosphorylation is critical for adaptation to cardiac stress. Circulation (2012) 1.19
Plasma biomarkers that reflect determinants of matrix composition identify the presence of left ventricular hypertrophy and diastolic heart failure. Circ Heart Fail (2011) 1.19
Acute traumatic aortic injury: imaging evaluation and management. Radiology (2008) 1.19
TNF-alpha and myocardial matrix metalloproteinases in heart failure: relationship to LV remodeling. Am J Physiol Heart Circ Physiol (2002) 1.17
Left ventricular form and function: scientific priorities and strategic planning for development of new views of disease. Circulation (2004) 1.16
Effects of age on plasma matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs). J Card Fail (2007) 1.16
A murine model of thoracic aortic aneurysms. J Surg Res (2003) 1.16
Changes in extracellular collagen matrix alter myocardial systolic performance. Am J Physiol Heart Circ Physiol (2003) 1.15
Effects of deletion of the matrix metalloproteinase 9 gene on development of murine thoracic aortic aneurysms. Circulation (2005) 1.15
Matrix metalloproteinase inhibition modifies left ventricular remodeling after myocardial infarction in pigs. J Thorac Cardiovasc Surg (2003) 1.13
Trafficking of the membrane type-1 matrix metalloproteinase in ischemia and reperfusion: relation to interstitial membrane type-1 matrix metalloproteinase activity. Circulation (2005) 1.11
The utility of positron emission tomography in staging of potentially operable carcinoma of the thoracic esophagus: results of the American College of Surgeons Oncology Group Z0060 trial. J Thorac Cardiovasc Surg (2007) 1.11
Underuse of surgical resection for localized, non-small cell lung cancer among whites and African Americans in South Carolina. Ann Thorac Surg (2008) 1.10
Local hydrogel release of recombinant TIMP-3 attenuates adverse left ventricular remodeling after experimental myocardial infarction. Sci Transl Med (2014) 1.08
Alterations in cultured myocardial fibroblast function following the development of left ventricular failure. J Mol Cell Cardiol (2006) 1.08
Analyzing Propensity Matched Zero-Inflated Count Outcomes in Observational Studies. J Appl Stat (2014) 1.07
Relationship between the temporal profile of plasma microRNA and left ventricular remodeling in patients after myocardial infarction. Circ Cardiovasc Genet (2011) 1.06
Infarct size reduction and attenuation of global left ventricular remodeling with the CorCap cardiac support device following acute myocardial infarction in sheep. Heart Fail Rev (2005) 1.06
Progressive induction of left ventricular pressure overload in a large animal model elicits myocardial remodeling and a unique matrix signature. J Thorac Cardiovasc Surg (2011) 1.06
Pressure overload-dependent membrane type 1-matrix metalloproteinase induction: relationship to LV remodeling and fibrosis. Am J Physiol Heart Circ Physiol (2012) 1.06
Matrix modulation and heart failure: new concepts question old beliefs. Curr Opin Cardiol (2005) 1.05
Targeted imaging of the spatial and temporal variation of matrix metalloproteinase activity in a porcine model of postinfarct remodeling: relationship to myocardial dysfunction. Circ Cardiovasc Imaging (2011) 1.04
Endothelin-A receptor inhibition after cardiopulmonary bypass: cytokines and receptor activation. Ann Thorac Surg (2008) 1.03
Differential effects of mechanical and biological stimuli on matrix metalloproteinase promoter activation in the thoracic aorta. Circulation (2009) 1.03
Selective induction of matrix metalloproteinases and tissue inhibitor of metalloproteinases in atrial and ventricular myocardium in patients with atrial fibrillation. Am J Cardiol (2006) 1.02
Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure. J Card Fail (2002) 1.01
Pulmonary segmentectomy: results and complications. Ann Thorac Surg (2003) 1.01